New Hampshire Medicaid GLP-1 Coverage 2026: Pattern #25 — Policy-Reversal Termination via Single DHHS Memo (October 9, 2025) + 4-Indication Carve-Out Without Published Thresholds + SB 455 Blocked 13–2 + KFF Four-State Elimination Cluster

New Hampshire Medicaid — administered by the New Hampshire Department of Health and Human Services (DHHS) Division of Medicaid Services for approximately 186,000 enrollees — terminated coverage of GLP-1 medications for obesity-only indications effective January 1, 2026. The legal instrument is a single one-page DHHS Provider Notification dated October 9, 2025 — the leanest termination paper trail in the 25-state Medicaid GLP-1 series. The fiscal driver is a $51 million budget cut on DHHS imposed by the 2025 NH Legislature, combined with Governor Kelly Ayotte’s direct assessment that GLP-1 obesity coverage was “a fairly significant cost driver.” The result: New Hampshire joins California (Pattern #2), Pennsylvania (Pattern #7), and South Carolina as the four states that the Kaiser Family Foundation classified in January 2026 as having eliminated GLP-1 coverage for obesity treatment. NH is the third state in this series from that four-state cluster — and the one with the most operationally ambiguous post-termination coverage architecture: four indications preserved (T2DM, MACE, OSA, MASH) but no published clinical criteria document with numeric thresholds for any of the three non-T2DM indications.

TL;DR — what NH Medicaid covers for GLP-1s in 2026

The October 9, 2025 DHHS Provider Notification — what it actually says

Unlike Pennsylvania’s termination (anchored in a formal Medical Assistance Bulletin, a Pennsylvania Bulletin legal notice, and a pre-existing state-regulation amendment), New Hampshire’s January 1, 2026 termination rests entirely on a single memorandum-style instrument. The NH DHHS Provider Notification dated October 9, 2025— addressed to “NH Medicaid Enrolled Providers” from the “NH Division of Medicaid Services” — is one page, unsigned by any individual, and cites no NH RSA, no He-W rule amendment, no formal P&T Committee action, and no Drug Utilization Review (DUR) Board action. It is the complete termination-authority instrument.

The notification’s operative clause verbatim:

“Effective January 1, 2026, New Hampshire Medicaid will no longer cover GLP-1 medications when prescribed solely for weight loss. These medications will continue to be covered when prescribed for other chronic health conditions.”

The drug list named in the notification verbatim:

“GLP-1 medications (such as Saxenda, Wegovy, and Zepbound and any generic versions) will no longer be reimbursed by Medicaid if prescribed exclusively for weight loss purposes.”

The four preserved indications, verbatim from the notification:

“Coverage will remain unchanged for members using GLP-1s as part of a treatment plan for other chronic health conditions such as the treatment of type 2 diabetes, major adverse cardiovascular events (MACE), severe obstructive sleep apnea and Metabolic Dysfunction-Associated Steatohepatitis (MASH).”

The notification’s “Provider Action Steps” section, verbatim:

“Review current treatment plans for Medicaid members prescribed GLP-1s.
Discuss alternative weight management options with affected members, such as:
• Medicaid-covered weight loss medications (if applicable)
• Physical therapy for deconditioning and home exercise programs
• Lifestyle modification programs offered by community organizations
Support members in transitioning to covered services or treatments that meet their clinical needs.”

The closing paragraph verbatim:

“We understand this change may be difficult for some members. Your role in helping them navigate alternative care options is essential. Thank you for your continued support in delivering high-quality care to our Medicaid population.

If there are questions on how one of the NH Medicaid Managed Care Organizations (MCO) handles the above information, please reach out to your MCO provider representative.

If there are any questions on this notice, please contact the Provider Relations Unit at (603) 223-4774 or (866) 291-1674.”

The notification is signed: “NH Medicaid Provider Relations” — with no individual name. The notification’s regulatory basis is the existing pharmacy program authority under NH He-W 570 (Pharmaceutical Services rule) and the federal optional-exclusion permissive authority at 42 U.S.C. § 1396r-8(d)(2)(A), which states verbatim: “The following drugs or classes of drugs, or their medical uses, may be excluded from coverage or otherwise restricted: (A) Agents when used for anorexia, weight loss, or weight gain.” NH was not federally required to terminate; it exercised discretion under that permissive authority.

The leanness of this paper trail is itself a YMYL-relevant data point. The October 9, 2025 notification is the only termination-authority document. There is no published NH administrative rule amendment, no formal DHHS rulemaking record, and no published DUR Board recommendation that predates or accompanies the termination. The article writer has verified this as of May 10, 2026: the NH He-W 570 framework at Cornell LII does not reflect a formal amendment adding GLP-1s to non-covered items, and the DHHS communications portal confirms the October 9, 2025 notification is the operative instrument.

What is still covered: T2DM + MACE + OSA + MASH

Type 2 diabetes (T2DM) — published criteria available

The NH FFS Medicaid GLP-1 Receptor Agonist Criteria, approved June 5, 2025, is the only indication-specific PA criteria document for any GLP-1 in the NH FFS pharmacy system. It covers T2DM-indicated GLP-1s exclusively. The medications listed in the criteria document verbatim: Trulicity (dulaglutide), Byetta (exenatide), Bydureon BCise (exenatide ER), Victoza (liraglutide), Xultophy (liraglutide/insulin degludec), Soliqua (lixisenatide/insulin glargine), Ozempic (semaglutide), Rybelsus (semaglutide), Mounjaro (tirzepatide). Wegovy, Zepbound, and Saxenda are not in the document.

The four approval criteria, verbatim:

“1. Patient has a diagnosis of a type 2 diabetes mellitus; AND
2. Patient age is supported by FDA-approved indication; AND
3. Medication requested will be used as an adjunct to diet and exercise; AND
4. Patient has had a trial of an oral antihyperglycemic.”

Length of approval: one year. The April 1, 2026 NH FFS PDL confirms the T2DM GLP-1 landscape verbatim (Endocrinology – GLP-1 Agonists and Combinations class, page 27):

• Preferred: Byetta, exenatide (generic for Byetta), Ozempic, Trulicity, Victoza
• Non-Preferred: Bydureon BCise, liraglutide (generic for Victoza), Mounjaro, Rybelsus, Soliqua, Symlin Pens, Xultophy
• PDL footnote: “Trial and failure of 2 Preferred products required prior to Non-Preferred products.”

The April 21, 2026 NH DUR Board agenda lists the GLP-1 criteria under “Review of Current Clinical Prior Authorization Criteria with Proposed Changes” with the “(DM)” suffix — the DUR Board’s own notation that this criteria covers the diabetes-indicated GLP-1s only.

MACE risk reduction (Wegovy) — no published NH criteria thresholds

The October 9, 2025 DHHS notification preserves coverage for GLP-1s used as part of a treatment plan for “major adverse cardiovascular events (MACE)” — the FDA-label CVD indication for Wegovy (semaglutide 2.4 mg, SELECT trial). As of May 10, 2026, no NH FFS clinical PA criteria document has been published for Wegovy MACE. There is no NH-published BMI threshold, no published cardiovascular-event documentation requirement, and no published step-therapy sequence for this indication.

Providers and members should be aware of the practical consequences: Wegovy MACE PA requests in the NH FFS population route through the generic Non-Preferred Drug PA Form, with the provider supplying FDA-label-indication documentation (established CVD plus obesity or overweight, per the SELECT trial FDA label). The Prime Therapeutics portal adjudicates the request on medical-necessity grounds. PBM response: within 24 hours per He-W 570.06(g). Approval duration: not centrally published for the MACE indication.

This is the key structural difference between NH and Massachusetts (Anchor #15): MA’s Pharmacy Facts #271 published a verbatim BMI threshold for MACE (BMI > 27 + established CVD). NH published nothing equivalent. Members seeking Wegovy for MACE in NH are relying on provider-supplied documentation and case-by-case adjudication, not a published criteria document they can verify in advance.

Severe obstructive sleep apnea (Zepbound) — no published AHI threshold

The October 9, 2025 notification preserves coverage for GLP-1s in the treatment of “severe obstructive sleep apnea” — the FDA-label OSA indication for Zepbound (tirzepatide, SURMOUNT-OSA trial). As of May 10, 2026, no NH FFS clinical PA criteria document has been published for Zepbound OSA. There is no published AHI cutoff, no published BMI floor, and no published PAP-adherence or PAP-intolerance documentation requirement.

For comparison: Ohio’s January 2026 Metabolic Modifiers criteria specify an AHI threshold; Massachusetts’s Pharmacy Facts #271 specifies BMI > 30 plus AHI > 15; Pennsylvania’s MAB2025112403 specifies BMI ≥ 35 plus PAP adherence or intolerance documentation. NH has published none of these equivalents. Zepbound OSA requests in NH proceed via the Non-Preferred Drug PA Form with the provider supplying AHI documentation and clinical history supporting the FDA label.

MASH (Wegovy) — no published fibrosis-stage requirement

The October 9, 2025 notification preserves coverage for “Metabolic Dysfunction-Associated Steatohepatitis (MASH)” — the FDA-label MASH indication for Wegovy (semaglutide, ESSENCE trial, noncirrhotic fibrosis F2/F3). As of May 10, 2026, no NH FFS clinical PA criteria document has been published for Wegovy MASH. There is no published fibrosis-stage requirement (F2/F3, or otherwise), no published liver-imaging or biopsy requirement, and no published hepatologist-or-gastroenterologist consultation requirement.

Wegovy MASH requests in NH proceed via the Non-Preferred Drug PA Form with the provider supplying fibrosis-staging documentation (FibroScan, FIB-4, ELF score, or liver biopsy) aligned with the FDA ESSENCE-trial label. PA is adjudicated on medical-necessity grounds by Prime Therapeutics.

The YMYL trap: no published NH FFS thresholds for three of four preserved indications

The operational reality after January 1, 2026: a member or provider in New Hampshire Medicaid cannot look up a published NH FFS document that specifies what BMI, AHI, or fibrosis score is required to qualify for Wegovy MACE, Zepbound OSA, or Wegovy MASH. The only published NH criteria document—the June 5, 2025 GLP-1 Receptor Agonist Criteria—covers T2DM only and does not list Wegovy, Zepbound, or Saxenda. The three non-T2DM carve-outs are real (the DHHS notification is verbatim and verified), but the operational pathway is case-by-case medical-necessity adjudication via the generic Non-Preferred Drug PA Form, not a standardized clinical-criteria checklist.

For context: Pennsylvania, Massachusetts, Washington, and Ohio all published indication-specific PA criteria documents with verbatim BMI thresholds, fibrosis-staging requirements, and AHI cutoffs for their GLP-1 non-obesity carve-outs. NH is the only state in the 25-state series that preserved all four non-weight-loss indications while publishing criteria documents for only one of them (T2DM). This asymmetry is not a coverage defect — the DHHS notification clearly preserves the three non-T2DM indications — but it means members and providers must submit a fully documented medical-necessity request rather than confirming against a published threshold table.

What changed January 1, 2026

Before January 1, 2026, New Hampshire Medicaid covered GLP-1 medications for chronic weight management. The Kaiser Family Foundation’s October 2025 Medicaid Budget Survey listed NH among 16 state Medicaid programs covering GLP-1s for obesity treatment under fee-for-service. New Hampshire was not on the KFF 13-state covering list published January 16, 2026. The transition occurred on a single date: January 1, 2026.

NH DHHS data, as reported by the NH Bulletin (William Skipworth, December 5, 2025), quantifies the shift:

• $49.5 million — annual NH Medicaid GLP-1 spending pre-termination (FY 2025-2026, DHHS data)
• $41 million — projected annual NH Medicaid GLP-1 spending post-termination, retaining T2DM/MACE/OSA/MASH (DHHS projection)
• ~$8.5 million — the projected annual additional cost of restoring obesity-indication coverage under SB 455 (Union Leader April 21, 2026, from the SB 455 fiscal note)
• $24.2 million — an alternative annual additional cost figure cited by the Concord Monitor (April 19, 2026) from a different fiscal-note iteration

The fiscal-figure variance across reporting outlets reflects different fiscal-note iterations and different SB 455 scope assumptions. The $49.5M/$41M DHHS-derived pair is the most authoritative single-document anchor for the pre-to-post-termination spending shift.

What ended on January 1, 2026:

• Coverage of Saxenda (liraglutide 3 mg) for chronic weight management — Saxenda has no FDA-label non-weight-loss indication and is therefore excluded outright with no carve-back-in pathway.
• Coverage of Wegovy (semaglutide 2.4 mg) for chronic weight management in the absence of MACE or MASH indication documentation.
• Coverage of Zepbound (tirzepatide) for chronic weight management in the absence of OSA documentation.
• All existing PA approvals for weight-management GLP-1 indications issued prior to October 9, 2025 — the provider notification window signaled no continuity-of-care extension through December 31, 2025 beyond the original PA approval term.

What did not change:

• T2DM-indicated GLP-1 coverage (Ozempic, Trulicity, Victoza, Mounjaro, Rybelsus, and others on the April 1, 2026 PDL) — unchanged from the pre-termination architecture.
• Coverage of non-GLP-1 anti-obesity medications (phentermine, Contrave/naltrexone-bupropion, Qsymia/phentermine-topiramate, Imcivree/setmelanotide for genetic conditions, Xenical/orlistat) under prior authorization per NH Healthy Families NH.PMN.50 and parallel MCO policies.
• The federal EPSDT (Early and Periodic Screening, Diagnostic, and Treatment) pathway for members under 21 years of age — NH has not published an EPSDT-specific GLP-1 carve-out, but the federal mandate under 42 U.S.C. § 1396d(r) applies to medically necessary care for pediatric Medicaid members regardless of the adult-coverage termination. Pediatric GLP-1 requests should be submitted with EPSDT medical-necessity documentation.

The broader population context: New Hampshire Medicaid covers approximately 186,000 enrollees, including approximately 92,583 unique Granite Advantage (Medicaid expansion) enrollees during fiscal year 2024, per the New Hampshire Fiscal Policy Institute. Granite Advantage members face the same obesity-coverage exclusion as the broader NH Medicaid population. The state’s approximately 54% female enrollment means the termination disproportionately affects adult women: approximately 30% of NH adult women experience obesity, per Business NH Magazine (December 8, 2025, citing Millicent Gorham, CEO of Alliance for Women’s Health and Prevention).

The three MCOs and their parallel terminations

New Hampshire’s Medicaid Care Management (MCM) program contracts with three managed care organizations under a September 1, 2024 – August 31, 2029 contract period. Together, these plans cover most NH Medicaid recipients (NH Healthy Families serves approximately 93,000 NH residents, roughly half of the 178,000 MCM-covered lives, per Healthcare Dive reporting on the 2024 contract). All three published parallel termination notices within five days of the DHHS October 9, 2025 notification.

AmeriHealth Caritas New Hampshire

AmeriHealth Caritas New Hampshire (part of the AmeriHealth Caritas Family of Companies) issued a Provider Communication on October 10, 2025 — one calendar day after the DHHS notification. The operative language verbatim:

“Per NH DHHS, effective January 1, 2026, New Hampshire Medicaid will no longer cover GLP-1 medications when prescribed solely for weight loss. These medications will continue to be covered when prescribed for other chronic health conditions.

What Providers Need to Know:
• GLP-1 medications (such as Saxenda, Wegovy, and Zepbound and any generic versions) will no longer be reimbursed by Medicaid if prescribed exclusively for weight loss purposes.
• Coverage will remain unchanged for members using GLP-1s as part of a treatment plan for other chronic health conditions such as the treatment of type 2 diabetes, major adverse cardiovascular events (MACE), severe obstructive sleep apnea and Metabolic Dysfunction-Associated Steatohepatitis (MASH).”

AmeriHealth Caritas NH provider contact: 1-888-599-1479.

NH Healthy Families (Centene Corporation)

NH Healthy Families — a Centene Corporation subsidiary — published a newsroom announcement on October 14, 2025 with parallel coverage language: “GLP-1 medications will no longer be covered when prescribed solely for weight loss” beginning January 1, 2026, with continued coverage “when prescribed for other chronic health conditions.”

NH Healthy Families’ anti-obesity pharmacy architecture is the most operationally explicit of the three MCOs. The plan’s Clinical Policy NH.PMN.50 “Anti-Obesity Medications”, effective 01.26 (last review 04.26), documents the explicit exclusion at every step in the PA ladder. The Description section lists six covered anti-obesity medications — Adipex-P (phentermine), Contrave (naltrexone/bupropion), Imcivree (setmelanotide), phentermine, Lomaira (phentermine), and Qsymia (phentermine/topiramate) — with Saxenda, Wegovy, and Zepbound conspicuously absent.

Initial Criteria (Adults), criterion 1, verbatim:

“Medication request is not a GLP-1 receptor agonist; AND”

Initial Criteria (Pediatric), criterion 1, verbatim:

“Medication request is not a GLP-1 receptor agonist; AND”

Continuation Criteria (all other agents), criterion 1, verbatim:

“Request is not for a GLP-1 receptor agonist; AND”

The policy’s Revision Log verbatim:

“10.25 — Policy developed.
11.25 — Added ‘must submit clinical chart notes’ and criteria for continuation to exclude GLP-1 receptor agonists.
04.26 — Added requirement for submission of weight and BMI and no utilization of multiple weight loss medications concurrently.”

The NH.PMN.50 Revision Log is itself significant: the policy was initially developed in October 2025 (in parallel with the DHHS notification), then revised in November 2025 to explicitly add GLP-1 receptor agonist exclusion language to the Continuation Criteria, and then revised again in April 2026 to strengthen documentation requirements for the remaining non-GLP-1 agents. This revision arc confirms ongoing active MCO-level policy management aligned with the DHHS termination.

The policy’s Important Reminder excerpt verbatim:

“Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.”

NH Healthy Families member/provider contact: 1-866-769-3085 or TTY 1-855-742-0123.

WellSense Health Plan NH (Express Scripts as PBM)

WellSense Health Plan NH — formerly Boston Medical Center HealthNet Plan — published the third MCO-level confirmation on its member-facing prescriptions page. The member notice verbatim:

“Effective January 1, 2026: GLP-1 medications prescribed solely for weight loss will no longer be covered by New Hampshire Medicaid.

If you are currently taking a GLP-1 for weight loss, we encourage you to contact your provider to discuss alternatives prior to the change going into effect on January 1, 2026.

Coverage for GLP-1s will remain unchanged and still require prior authorization (PA) when used to treat other health conditions.”

WellSense NH uses Express Scripts as its pharmacy benefit manager, per the WellSense NH prescriptions page reference to the Express Scripts portal for the drug list. Members enrolled in WellSense NH can search the Express Scripts formulary at the member portal.

The synchronization pattern

All three MCOs published their parallel notices within five days of each other (October 10–14, 2025), one to five days after the DHHS October 9, 2025 notification. The near-simultaneous publication reflects the standard MCM contract alignment: NH’s September 1, 2024 – August 31, 2029 MCM contract requires all three plans to implement DHHS clinical policy changes across the managed-care population. The result is that for the overwhelming majority of NH Medicaid enrollees (MCM-enrolled), the January 1, 2026 termination was communicated through their MCO rather than through the DHHS notification directly. The underlying coverage decision is uniform: no obesity-indication GLP-1 coverage, preserved T2DM/MACE/OSA/MASH coverage, via any of the three MCM plans or the FFS population.

FFS pharmacy benefit manager: Prime Therapeutics State Government Solutions LLC

For the FFS (fee-for-service) NH Medicaid population, the Pharmacy Benefit Administrator is Prime Therapeutics State Government Solutions LLC— confirmed by the footer attribution on the NH FFS Medicaid PDL (verbatim: “© 2019–2026 Prime Therapeutics Management LLC, a Prime Therapeutics LLC company”) and by the NH DHHS Medicaid Pharmacy Benefit Management page. Prime Therapeutics hosts the NH Medicaid portal at nh.primetherapeutics.com, which is the authoritative source for the FFS PDL, clinical PA criteria documents, DUR Board agendas, and provider notifications.

Prime Therapeutics also publishes the NH FFS Medicaid DUR Board agendas. The April 21, 2026 DUR Board agenda listed the “GLP-1 Receptor Agonist (DM)” criteria under “Review of Current Clinical Prior Authorization Criteria with Proposed Changes” — meaning the T2DM-only criteria document is currently in active DUR Board review for potential revisions. The “(DM)” suffix in the DUR Board agenda is the operational signal that the document scope remains diabetes-only: there is no parallel “(MACE)” or “(OSA)” criteria document under DUR Board review as of May 10, 2026.

For the MCM population, the PBM architecture differs by plan:

• NH Healthy Families (Centene): Centene’s centralized clinical-policy framework (NH.PMN.50 and related policies).
• WellSense NH: Express Scripts (per the member prescriptions portal).
• AmeriHealth Caritas NH: AmeriHealth Caritas pharmacy benefit platform.

The underlying coverage decision (no obesity coverage; preserved T2DM/ MACE/OSA/MASH) is uniform across all three MCM plans and the FFS population, per the DHHS October 9, 2025 notification. Members enrolled in different MCM plans may experience different PA forms, different appeal contact numbers, and different formulary search portals — but the operative coverage determination is the same.

SB 455 (Sen. Prentiss) — blocked 13–2

On March 5, 2026, the New Hampshire Senate passed Senate Bill 455 (SB 455), 194th General Court 2026 session, sponsored by Sen. Suzanne M. Prentiss (D-Lebanon, District 5). The bill was the primary 2026 legislative vehicle for restoring or expanding GLP-1 coverage for NH Medicaid and commercial insurance enrollees.

The bill required health insurance to cover GLP-1 medications for individuals with BMI of 40 or higher, or BMI of 35 or higher with at least one additional health condition. The Senate subsequently lowered these thresholds. A public hearing was held April 15, 2026, before the House Commerce and Small Business Committee (Room 229).

Sen. Prentiss, the prime sponsor, testified verbatim (Concord Monitor, April 19, 2026):

“I have seen what this can do and what it can prevent.”
“This will be a policy shift for us. Right now our system pays for the more expensive procedures.”
“It’s not cosmetic. Obesity is a medical condition.”
“By driving down obesity, we can drive down the costs that are related to it.”

Dr. Sarah Finn, Section Chief for Obesity Medicine at Dartmouth Health, testified verbatim (Union Leader, April 21, 2026):

“On one day we had 1,100 denials for GLP agonists.”
“I don’t have options except for bariatric surgery for Medicaid.”
“If a patient over time is taking these medications, we are paying less for them.”

Timisha Malone, a clinical social worker from Salem, testified verbatim (Union Leader, April 21, 2026):

“Access to care is determined not by medical need but by financial privilege.”

Dr. Jonathan Ballard, Chief Medical Officer of NH DHHS, testified against restoration verbatim (Concord Monitor, April 19, 2026):

“The department does not have this money today. So, living within the realities of our current budget, there will be significant trade-offs.”
“I have not found a study that says there will be cost savings.”
“I fully expect the price will come down in years to come.”

On April 21, 2026, the House Commerce and Small Business Committee voted 13–2 to recommend the bill as Inexpedient to Legislate — the procedural mechanism for killing a bill without a floor vote. The two opposing votes were cast by Reps. Julie Miles (R-Merrimack) and Jared Sullivan (D-Bethlehem).

The Committee Chairman, Rep. John Hunt (R-Rindge), stated verbatim (Union Leader, April 21, 2026, updated April 29, 2026):

“Given the governor has already stopped GLPs for Medicaid, there is no reason for us to be passing this bill at this time.”

Chairman Hunt’s statement is the single clearest articulation of executive-legislative alignment in the 25-state series: the governor administratively terminated obesity coverage, and the legislature declined to restore it through the primary available legislative vehicle, citing the executive’s existing decision as dispositive. The House is expected to endorse the ITL recommendation on the House floor.

As of May 10, 2026, no NH RSA section has been enacted or amended to either codify the January 1, 2026 termination or restore obesity-indication GLP-1 coverage. The termination operates entirely via DHHS administrative authority under existing NH He-W 570 and 42 U.S.C. § 1396r-8(d)(2)(A). There is no NH House bill identified as advancing through the 194th General Court 2026 session as a Medicaid-specific obesity-coverage vehicle.

Dartmouth Rockefeller Center cost-benefit analysis (March 9, 2026)

The most-cited academic anchor in the SB 455 legislative debate is the Dartmouth Rockefeller Center for Public Policy cost-benefit analysis, titled “Cost-Benefit Analysis of GLP-1 Coverage for Obesity in New Hampshire,” published March 9, 2026 by Alan Cui, Annabelle Pietryka, and Lucia Vitali. The study was published at rockefeller.dartmouth.edu/node/21091.

Headline figures, per Concord Monitor reporting (April 19, 2026):

• $4.1 billion — 25-year projected health care savings from restoring GLP-1 coverage for obesity
• $2.7 billion — 25-year projected taxpayer cost
• Net: approximately $1.4 billion projected net benefit over 25 years

These figures are outputs of a cost-benefit projection model, not empirical accounting. The 25-year horizon involves assumptions about medication adherence, downstream health-condition rates, healthcare utilization, and Medicaid actuarial projections that are inherently speculative at this time horizon. The article writer notes that the Dartmouth Rockefeller Center is an academic policy center, not a state-agency fiscal note. The underlying PDF methodology details were not directly extracted verbatim during the verifier-brief compilation for this article; the $4.1B/$2.7B figures are cited as reported by the Concord Monitor from the March 9, 2026 publication.

The study was the primary academic rebuttal to the DHHS fiscal position. Dr. Ballard’s April 15, 2026 testimony — “I have not found a study that says there will be cost savings” — was directly responsive to the Dartmouth analysis. The 13–2 committee vote reflected the legislature’s decision to weight the current-year budget constraint (a real $51M DHHS cut in the 2025 biennial budget) over a 25-year modeled projection. This is a contested policy-economics question; this article does not endorse either the Dartmouth model’s projections or the DHHS fiscal-constraints position. Both are documented as primary-source anchors in the legislative record.

Appeals: NH He-W 200 administrative hearings

When an NH Medicaid pharmacy prior-authorization request is denied, the appeal process is anchored in two administrative rule frameworks: NH He-W 570.06 (Prior Authorization, the PA-specific procedural rule) and the NH He-W 200 series (Administrative Hearings Process, the general fair-hearing framework).

The 30-calendar-day appeal window

NH He-W 570.06 states verbatim:

“When a prior authorization request is denied, the department must provide written notice to the recipient and prescribing practitioner, including information that a denial may be appealed within 30 calendar days.”

This 30-day window runs from the date of the written denial notice. It is shorter than Tennessee’s 60-day window and shorter than Pennsylvania’s 30-day window with a 15-day “aid-pending-appeal” sub-window. The practical consequence: a member or prescribing provider who receives a denial for Wegovy MACE, Zepbound OSA, or Wegovy MASH must respond within 30 calendar days. Do not wait for a second denial or a formulary review cycle to begin the appeal process.

How to file a fair hearing

The operational appeal pathway:

1. Receive written denial notice from Prime Therapeutics (FFS) or the MCO pharmacy benefit administrator. The notice must include the reason for denial and information about the 30-day appeal window.
2. For FFS members: file the appeal request with the NH DHHS Administrative Appeals Unit. Contact the Provider Relations Unit at (603) 223-4774 or (866) 291-1674 for guidance on the filing process.
3. For MCO members (AmeriHealth Caritas NH, NH Healthy Families, WellSense NH): the MCO internal appeal process must be exhausted first. Each MCO has its own internal grievance/appeal timeline. After the MCO internal appeal is resolved, the member may request a DHHS fair hearing.
4. The DHHS hearing is conducted by a DHHS hearings officer under the NH He-W 200 series Administrative Hearings Process. A decision is rendered with a right to further appeal to the NH Superior Court under NH RSA 541-A (Administrative Procedure Act).
5. 72-hour emergency supply: Per 42 U.S.C. § 1396r-8(d)(5)(B) and the March 4, 2026 DHHS notification verbatim: “federal statute requires Medicaid programs (Fee-for-Service and managed care) provide payment for dispensing of at least a 72-hour supply for any drugs requiring prior authorizations if prior authorization cannot be obtained outside of Medicaid business hours.”

What a fair hearing can and cannot do

A fair hearing can reverse an adjudication-error denial — for example, a Wegovy MACE denial where the clinical documentation establishing established cardiovascular disease and the FDA-label indication was submitted but incorrectly evaluated by the PBM reviewer; or a Zepbound OSA denial where AHI documentation was present but not reviewed. If the denial was caused by an error in applying the medical-necessity criteria to the submitted documentation, a DHHS hearings officer can reverse it.

A fair hearing cannot reverse a policy-level determination. Wegovy, Zepbound, or Saxenda denials for the pure weight-management indication are a coverage policy decision — not a PA adjudication error — and cannot be overridden through fair hearing. A hearings officer cannot add a drug to the PDL or override the October 9, 2025 DHHS notification.

The strongest exception pathway is for members under 21 years of age: the federal EPSDT mandate under 42 U.S.C. § 1396d(r) requires that medically necessary services be covered for pediatric Medicaid members. A pediatric GLP-1 denial for obesity treatment may be challengeable on EPSDT grounds — the argument being that the weight-management drug is medically necessary for the specific pediatric patient’s condition regardless of the adult- coverage termination. NH has not published a specific EPSDT GLP-1 carve-out protocol (unlike Massachusetts, which explicitly published EPSDT coverage language in Pharmacy Facts #271). Pediatric members or their providers asserting EPSDT coverage should document the medical necessity of the specific drug for the specific patient.

How NH compares: vs. PA (#7), MA (#15), CA (#2)

New Hampshire is Pattern #25 in the 50-state Medicaid GLP-1 series — the third state from the KFF January 2026 four-state elimination cluster (CA + NH + PA + SC). The taxonomy table for the 25-state series:

vs. Pennsylvania (Anchor #7) — same effective date, leaner NH authority: Both states terminated January 1, 2026. PA’s authority is a formal Medical Assistance Bulletin (MAB2025112403, November 24, 2025) supplemented by 55 Pa. Code § 1121.54 (amended January 2, 2026) and a Pennsylvania Bulletin legal notice (55 Pa.B. 8828, December 27, 2025). NH’s authority is a single one-page DHHS Provider Notification (October 9, 2025) with no parallel state-regulation anchor. PA gave approximately 38 days advance notice; NH gave approximately 84 days. PA published detailed, verbatim PA criteria for its MACE/MASH/OSA carve-outs (BMI thresholds, step-therapy sequences, approval durations) in MAB2025112403. NH published none for MACE/OSA/MASH. PA preserved a narrower set of non-weight-loss indications (no standalone T2DM + obesity coverage without a separate PA pathway); NH preserved four indications with T2DM as the most operationally defined.

vs. Massachusetts (Anchor #15) — same four-indication architecture, NH is earlier and less defined: MA’s prospective July 1, 2026 termination converges on the same four indications (T2DM + MACE + MASH + OSA) as NH’s January 1, 2026 architecture. MA published Pharmacy Facts #271 with verbatim BMI thresholds (MACE: BMI > 27 + established CVD; OSA: BMI > 30 + AHI > 15) and fibrosis-stage requirements (MASH: F2/F3, hepatologist/gastroenterologist consultation). NH published none of these equivalents. NH’s January 1, 2026 implementation is the “same four-indication architecture but without the published threshold table.”

vs. California (Anchor #2) — different carve-out scope: CA terminated January 1, 2026 with a narrow Medi-Cal Rx alert, then reinstated Wegovy MASH only in April 2026 via the CDL ICD-10 K76.0/K75.8 mechanism. NH terminated with four preserved indications from day one — there is no NH equivalent of CA’s “termination then partial carve-back-in” sequence. NH’s post-termination architecture is structurally broader than CA’s MASH-only reinstatement.

vs. New York (Anchor #3) — NH carve-outs broader but less operationally defined: NY preserves Wegovy MACE through the NYRx DUR pathway (BMI ≥ 40 + established CVD + lifetime two-attempt limit — stricter than FDA label). NH preserves MACE + OSA + MASH without equivalent published numeric thresholds — NH’s carve-out scope is broader on the indication dimension but less defined on the criteria dimension.

What NH Medicaid patients can do in 2026

This section documents the verified pathways available to NH Medicaid members who lost obesity-indication GLP-1 coverage as of January 1, 2026. This is not medical advice; individual outcomes depend on clinical documentation, MCO adjudication, and current policy.

Step 1: Determine if a non-obesity FDA-label indication applies

Before abandoning GLP-1 therapy, work with your prescriber to determine whether a documented non-weight-loss FDA-label indication applies:

• T2DM: Diabetes-indicated GLP-1s (Ozempic, Trulicity, Victoza, Mounjaro) remain covered with PA under the published GLP-1 Receptor Agonist Criteria (T2DM diagnosis + age-supported + adjunct to diet/exercise + prior oral antihyperglycemic trial).
• Wegovy MACE: If you have established cardiovascular disease (prior MI, stroke, or symptomatic PAD) and meet the FDA-label SELECT trial criteria (BMI ≥ 27 + established CVD), submit a Non-Preferred Drug PA Form with documentation of the CVD indication.
• Zepbound OSA: If you have documented obstructive sleep apnea (AHI established by sleep study) meeting the FDA-label SURMOUNT-OSA criteria (BMI ≥ 30 + moderate-to-severe OSA), submit a Non-Preferred Drug PA Form with sleep study documentation.
• Wegovy MASH: If you have metabolic dysfunction- associated steatohepatitis with fibrosis staging (F2/F3 by FibroScan, FIB-4, ELF score, or liver biopsy) meeting the ESSENCE trial criteria, submit a Non-Preferred Drug PA Form with hepatology documentation.

Step 2: Appeal an incorrect denial

If you submitted a Non-Preferred Drug PA Form for MACE, OSA, or MASH and received a denial, review the denial notice within the 30-calendar-day appeal window under NH He-W 570.06. Check whether the denial was:

• A policy-level denial (no MACE/OSA/MASH coverage for your indication) — a hearings officer cannot override this; escalate to the EPSDT pathway if under 21.
• An adjudication-error denial (the documentation was present but incorrectly evaluated) — file an appeal with the DHHS Administrative Appeals Unit (FFS) or the MCO internal-appeal process (MCM).

Contact the Provider Relations Unit at (603) 223-4774 or (866) 291-1674. For MCO members, contact your MCO member services: AmeriHealth Caritas NH at 1-888-599-1479, NH Healthy Families at 1-866-769-3085, or WellSense NH via the member portal.

Step 3: Non-GLP-1 anti-obesity medications remain covered

Per NH Healthy Families NH.PMN.50 (the most operationally documented MCO anti-obesity policy in NH), the following non-GLP-1 anti-obesity medications remain available on prior authorization:

• Phentermine (generic, Adipex-P, Lomaira) — approved up to 9 months; BMI ≥ 30 or ≥ 27 with risk factors; requires 3-month low-calorie diet trial documentation. Age minimum > 16.
• Contrave (naltrexone/bupropion) — PA required; same BMI/diet-trial/physical-activity criteria. Age minimum > 18.
• Qsymia (phentermine/topiramate ER) — PA required; same ladder. Age minimum > 18.
• Imcivree (setmelanotide) — PA required; limited to confirmed POMC/PCSK1/LEPR genetic deficiency or Bardet-Biedl syndrome by genetic testing; age > 6.

Continuation criteria for non-GLP-1 agents under NH.PMN.50 include a 5% weight-reduction-from-baseline requirement after 6 months of therapy for adults. Clinical chart notes confirming low-calorie diet adherence and physical activity are required.

Step 4: Commercial insurance migration

Members who obtain commercial insurance coverage (employer-sponsored, ACA marketplace, or Medicare Advantage, if transitioning to Medicare-eligible age) should independently verify GLP-1 formulary status with the new plan. NH Medicaid-to-commercial transitions are subject to marketplace enrollment windows; consult the NH Insurance Department or a navigator for eligibility and timing guidance. This article does not document NH commercial insurance GLP-1 coverage requirements, which vary by plan.

Step 5: Cash-pay pathways

Cash-pay GLP-1 options exist outside of NH Medicaid, but members should understand critical limitations before pursuing them:

• LillyDirect Foundayo (orforglipron, oral): Eli Lilly’s direct-pay program. Not an NH Medicaid benefit. Cost and availability subject to change.
• NovoCare (Novo Nordisk patient assistance): income- and-eligibility-gated program for semaglutide. Actively enrolled Medicaid members may not qualify during enrollment; verify eligibility before applying.
• Compounded GLP-1 sourcing: The FDA removed semaglutide and tirzepatide from the Drug Shortage List in mid-2025, ending the 503A/503B compounding pathway for these molecules at accredited pharmacies. Compounded GLP-1 sourcing from non-FDA- registered sources is not an NH Medicaid benefit and carries YMYL-relevant safety risks. This article does not endorse any compounding pharmacy source.

Sources

Primary-source URLs for all claims in this article:

• NH DHHS Provider Notification October 9, 2025: nh.primetherapeutics.com/documents/51139/51630/Notification%2010.09.2025%20-%20GLP-1%20Coverage%20Change/218c7285-7968-9484-a244-859e0741eeba
• NH FFS Medicaid PDL effective April 1, 2026: nh.primetherapeutics.com/documents/51139/51633/Preferred%20Drug%20List%20-%20Effective%204.1.2026/cd3e6793-b2a7-ccf0-1c36-70c18f52ee31
• NH FFS GLP-1 Receptor Agonist Criteria (T2DM only), approved June 5, 2025: nh.primetherapeutics.com/documents/51139/51621/GLP-1%20Receptor%20Agonist%20Criteria/9105e0b5-0a2e-48dc-d176-594ab9907de5
• AmeriHealth Caritas NH Provider Communication October 10, 2025: amerihealthcaritasnh.com/content/dam/amerihealth-caritas/acnh/pdf/provider/updates/2025/20251010-change-for-glp1-medications.pdf.coredownload.inline.pdf
• NH Healthy Families Newsroom October 14, 2025: nhhealthyfamilies.com/newsroom/glp-1-medications-change-in-coverage-effective-january-1--2026.html
• NH Healthy Families Clinical Policy NH.PMN.50 Anti-Obesity Medications: nhhealthyfamilies.com/content/dam/centene/NH%20Healthy%20Families/Medicaid/pdfs/NH.PMN.50%20Anti-Obesity%20Medications.pdf
• WellSense NH Member Notice (Prescriptions page): wellsense.org/members/nh/new-hampshire-medicaid/prescriptions/
• KFF Medicaid GLP-1 Coverage page, January 16, 2026: kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s/
• 42 U.S.C. § 1396r-8(d)(2)(A) (Cornell LII): law.cornell.edu/uscode/text/42/1396r-8
• NH He-W 570 (Cornell LII): law.cornell.edu/regulations/new-hampshire/title-He/subtitle-He-W/chapter-He-W-500/part-He-W-570
• Dartmouth Rockefeller Center cost-benefit analysis, March 9, 2026: rockefeller.dartmouth.edu/node/21091